Table 1.
Current clinical trials targeting mitochondrial dysfunction in neurodegenerative diseases.
| ID | Treatment | Phase | N |
|---|---|---|---|
| Alzheimer's disease | |||
| NCT05617508 | NR | N/A | 80 |
| NCT04430517 | NR | I | 50 |
| NCT05040321 | MIB-626 | I/II | 50 |
| NCT04842552 | Hydralazine | III | 424 |
| NCT05591027 | Centella asiatica product | I | 48 |
| NCT04740580 | Glycine, NAC | I | 52 |
| NCT05081219 | Insulin, empagliflozin | II | 60 |
| NCT04018092 | Photobiomodulation | II | 168 |
| NCT04784416 | Photobiomodulation | II | 125 |
| Amyotrophic lateral sclerosis | |||
| NCT04820478 | Beta hydroxybutyrate ester | N/A | 76 |
| NCT04244630 | Antioxidant supplements | II | 60 |
| Huntington's disease | |||
| NCT01502046 | THC and CBD | II | 25 |
| Parkinson's disease | |||
| NCT04477161 | Oral Ketone Esters | N/A | 10 |
| NCT03840005 | Ursodeoxycholic acid | II | 31 |
| NCT04044131 | Serine, l-carnitine, NAC, NR | II | 120 |
| NCT05214287 | Intermittent hypoxia therapy | I, II | 29 |
| NCT04768023 | Vitamin D3 | N/A | 50 |
A current list of ongoing clinical trials ascertained from ClinicalTrials.gov. The following search terms were used: Alzheimer's Disease, Amyotrophic lateral sclerosis, ALS, Lou Gehrig's, Huntington's Disease, Parkinson's Disease, Parkinsonism, mitochondria, mitochondrial, bioenergetics. Abbreviations: N – number of participants, NR – nicotinamide riboside, NAC – N-acetylcysteine, THC – Tetrahydrocannabinol, CBD – Cannabidiol.